{Reference Type}: Journal Article
{Title}: Combined treatment of All-trans retinoic acid with Tamoxifen suppresses ovarian cancer.
{Author}: Xu R;Yang X;Tang B;Mao Y;Jiang F;
{Journal}: Cancer Chemother Pharmacol
{Volume}: 0
{Issue}: 0
{Year}: 2024 May 7
{Factor}: 3.288
{DOI}: 10.1007/s00280-024-04671-7
{Abstract}: BACKGROUND: Ovarian cancer is a malignant tumor of the female reproductive system, and its mortality rate is as high as 70%. Estrogen receptor α (ERα)-positive ovarian cancer accounted for most of all ovarian cancer patients. ERα can promote the growth and proliferation of tumors.
METHODS: The combined effect of All-trans retinoic acid (ATRA) and tamoxifen was obtained by the combination screening of tamoxifen and compound library by MTS. In addition, colony formation assay, flow cytometry analysis, immunofluorescence staining, quantitative real-time polymerase chain reaction (PCR), western blot, and tumor xenotransplantation models were used to further evaluate the efficacy of tamoxifen and ATRA in vitro and in vivo for ER-α-positive ovarian cancer.
RESULTS: In our study, we found that All-trans retinoic acid (ATRA) can cooperate with tamoxifen to cause cell cycle arrest and apoptosis and inhibit ERα-positive ovarian cancer in vivo and in vitro. Further exploration of the mechanism found that ATRA can Inhibit genes related to the ERα signaling pathway, enhance the sensitivity of ERα-positive ovarian cancer cells to tamoxifen, and ascertain the effectiveness of tamoxifen and ATRA as treatments for ovarian cancer with an ERα-positive status.
CONCLUSIONS: Combination of ATRA and tamoxifen is a new way for the treatment of ERα-positive ovarian cancer.